We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.525 | 1.06% | 50.095 | 50.09 | 50.10 | 50.36 | 49.9508 | 50.23 | 1,333,760 | 20:40:31 |
From Nov 2023 to May 2024
By Pierre Bertrand
Sanofi said a second phase three trial of Dupixent met its primary endpoint with what the company said was overwhelming efficacy.
Sanofi said that its Notus trial confirmed positive published results from the Phase 3 Boreas trial.
The Notus trial found that the treatment "significantly reduced exacerbations" and that treatment with Dupixent led to rapid and significant improvements in lung function for patients with the life-threatening respiratory disease, COPD.
"These results were from an interim analysis and, given the overwhelming positive efficacy of the primary endpoint, will be considered the primary analysis of the trial," Sanofi said.
It added that it and Regeneron plan to submit these latest findings, in addition to the data from the Boreas trial, to the U.S. Food and Drug Administration by the end of the year.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 27, 2023 02:25 ET (07:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
